Disabling the Nuclear Translocalization of RelA/NF-κB by a Small Molecule Inhibits Triple-Negative Breast Cancer Growth
Open Access
- 1 July 2021
- journal article
- research article
- Published by Taylor & Francis in Breast Cancer: Targets and Therapy
- Vol. ume 13, 419-430
Abstract
Introduction: Constitutive activation of NF-κB has been implicated as being contributive to cancer cell growth, drug resistance, and tumor recurrence in many cancers including breast cancer. Activation of NF-κB leads to nuclear translocation of RelA, a critical component of the NF-κB transcription factor complex, which subsequently binds to specific DNA sites and activates a multitude of genes involved in diverse cell functions. Studies show that triple-negative breast cancer (TNBC) cells possess constitutively active NF-κB and concomitantly have higher levels of nuclear localization of RelA than cytoplasmic RelA. This feature is considered to be associated with the response to chemotherapy. However, currently, there is no specific inhibitor to block nuclear translocation of RelA. Methods: A structure-based approach was used to develop a small-molecule inhibitor of RelA nuclear translocation. The interaction between this molecule and RelA was verified biophysically through isothermal titration calorimetry and microscale thermophoresis. TNBC cell lines MDA-MB-231 and MDA-MB-468 and a human TNBC xenograft model were used to verify in vitro and in vivo efficacy of the small molecule, respectively. Results: We found that the small molecule, CRL1101, bound specifically to RelA as indicated by the biophysical assays. Further, CRL1101 blocked RelA nuclear translocation in breast cancer cells in vitro, and markedly reduced breast tumor growth in a triple-negative breast cancer xenograft model. Conclusion: Our study demonstrates that CRL1101 may lead to new NF-κB-targeted therapeutics for TNBC. Further, blocking of nuclear translocation of shuttling transcription factors may be a useful general strategy in cancer drug development.Keywords
This publication has 44 references indexed in Scilit:
- Collaboration gets the most out of softwareeLife, 2013
- Overexpression of p65 attenuates celecoxib-induced cell death in MDA-MB-231 human breast cancer cell lineCancer Cell International, 2013
- TWIST1 associates with NF-κB subunit RELA via carboxyl-terminal WR domain to promote cell autonomous invasion through IL8 productionBMC Biology, 2012
- Subtype and pathway specific responses to anticancer compounds in breast cancerProceedings of the National Academy of Sciences, 2011
- Disabling the mitotic spindle and tumor growth by targeting a cavity-induced allosteric site of survivinOncogene, 2011
- NF-κB, stem cells and breast cancer: the links get strongerBreast Cancer Research, 2011
- Obesity Is Associated with Inflammation and Elevated Aromatase Expression in the Mouse Mammary GlandCancer Prevention Research, 2011
- Inhibiting NF-κB activation by small molecules as a therapeutic strategyBiochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms, 2010
- Is NF-κB a good target for cancer therapy? Hopes and pitfallsNature Reviews Drug Discovery, 2009
- Polymersomes: A new multi-functional tool for cancer diagnosis and therapyMethods, 2008